T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1526
Avista
AVA
$3.28B
| $3.35M | ﹤0.01% |
87,031
+3,067
| +4% | +$120K |
|
1527
Trex
TREX
$5.06B
| $3.35M | ﹤0.01% |
95,451
-645,280
| -87% | -$26.1M |
|
1528
H.B. Fuller
FUL
$3.34B
| $3.35M | ﹤0.01% |
56,297
+2,411
| +4% | +$142K |
|
1529
Perdoceo Education
PRDO
$1.99B
| $3.35M | ﹤0.01% |
114,052
-112,027
| -50% | -$3.54M |
|
1530
Cousins Properties
CUZ
$4.89B
| $3.34M | ﹤0.01% |
129,491
+6,859
| +6% | +$178K |
|
1531
Renasant Corp
RNST
$3.97B
| $3.34M | ﹤0.01% |
94,781
+2,486
| +3% | +$88.1K |
|
|
PRMB
1532
Primo Brands
PRMB
$9B
| $3.33M | ﹤0.01% |
203,594
-278,744
| -58% | -$5.15M |
|
1533
Rocket Pharmaceuticals
RCKT
$369M
| $3.32M | ﹤0.01% |
944,873
-116,422
| -11% | -$399K |
|
1534
Unifirst Corp
UNF
$5.2B
| $3.31M | ﹤0.01% |
17,164
+517
| +3% | +$87.3K |
|
1535
BGC Group
BGC
$5.28B
| $3.3M | ﹤0.01% |
369,809
+10,308
| +3% | +$92.8K |
|
1536
Exponent
EXPO
$3.19B
| $3.3M | ﹤0.01% |
47,525
+4,550
| +11% | +$320K |
|
1537
Independent Bank
INDB
$4.06B
| $3.27M | ﹤0.01% |
44,785
+2,031
| +5% | +$144K |
|
1538
California Resources
CRC
$4.79B
| $3.27M | ﹤0.01% |
73,143
+10,677
| +17% | +$507K |
|
1539
Iovance Biotherapeutics
IOVA
$3.02B
| $3.25M | ﹤0.01% |
1,191,828
-866,190
| -42% | -$2M |
|
|
MZTI
1540
The Marzetti Company
MZTI
$3.17B
| $3.25M | ﹤0.01% |
19,773
+2,140
| +12% | +$357K |
|
1541
XP
XP
$8.13B
| $3.24M | ﹤0.01% |
198,103
+11,164
| +6% | +$197K |
|
1542
Bankunited
BKU
$3.43B
| $3.24M | ﹤0.01% |
72,674
-7,783
| -10% | -$322K |
|
1543
Franklin Electric
FELE
$4.67B
| $3.24M | ﹤0.01% |
33,908
+427
| +1% | +$40.8K |
|
1544
Signet Jewelers
SIG
$3.52B
| $3.24M | ﹤0.01% |
39,049
+1,671
| +4% | +$159K |
|
1545
California Water Service
CWT
$3.1B
| $3.22M | ﹤0.01% |
74,380
-77,021
| -51% | -$3.51M |
|
1546
Graham Holdings Company
GHC
$5.03B
| $3.22M | ﹤0.01% |
2,930
+88
| +3% | +$94.1K |
|
1547
MDU Resources
MDU
$4.35B
| $3.22M | ﹤0.01% |
164,813
+10,056
| +6% | +$198K |
|
1548
Whirlpool
WHR
$2.7B
| $3.22M | ﹤0.01% |
44,603
+1,971
| +5% | +$146K |
|
1549
Viking Therapeutics
VKTX
$3.87B
| $3.21M | ﹤0.01% |
91,223
+5,732
| +7% | +$203K |
|
1550
Americold
COLD
$4.25B
| $3.2M | ﹤0.01% |
248,888
+13,988
| +6% | +$171K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.